Share This Page
Drug Price Trends for sulfadiazine
✉ Email this page to a colleague
Average Pharmacy Cost for sulfadiazine
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SULFADIAZINE 500 MG TABLET | 42806-0757-60 | 14.97827 | EACH | 2026-03-18 |
| SULFADIAZINE 500 MG TABLET | 62135-0842-60 | 14.97827 | EACH | 2026-03-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Sulfadiazine
What Is the Current Market Size and Demand for Sulfadiazine?
Sulfadiazine, a broad-spectrum sulfonamide antibiotic, primarily treats bacterial infections such as toxoplasmosis, chlamydia, and certain skin infections. Its usage has declined in developed countries due to newer antibiotics but remains relevant in specific regions and for certain indications.
Global Market Size
As of 2022, the global antibiotic market is valued at approximately USD 57.6 billion, with sulfonamides accounting for roughly 3-5% of this segment, equating to USD 1.7-2.9 billion. Sulfadiazine constitutes a minor share, estimated around USD 100-250 million domestically and internationally, with rising demand in low- to middle-income countries for targeted infectious disease treatments.
Regional Demand Dynamics
- South Asia and Africa: High demand for inexpensive antibiotics to treat malaria-related infections and bacterial skin conditions.
- Europe and North America: Decline due to resistance issues and regulatory restrictions. Small but steady demand for specific indications.
- Middle East and Latin America: Moderate demand driven by infectious disease prevalence and limited access to newer antibiotics.
Key Drivers
- Resistance to current frontline antibiotics.
- Limited access to advanced medications in developing regions.
- Use in ophthalmic preparations and topical formulations.
- Growing prevalence of toxoplasmosis and chlamydia infections.
Supply Chain Considerations
Major producers include generic pharmaceutical companies in India, China, and Europe. Several APIs are produced under WHO prequalification standards, supporting export to underserved markets.
What Are the Current Pricing Trends and Regulatory Factors?
Typical Pricing Range
- API Level: USD 0.30-0.60 per gram, depending on purity, sourcing, and volume size.
- Finished Dosage Forms: Tablets 500 mg range from USD 0.10 to USD 0.50 per tablet, varying by region and distributor.
Regulatory Landscape
- United States: Sulfadiazine is not approved for new use but can be compounded or used off-label. Marketing restrictions limit new entrants.
- Europe: Limited approval for specific indications; regulatory authorities emphasize antimicrobial stewardship.
- India and China: APIs are produced at scale, with some export restrictions for raw material integrity.
Price Influences
- The rise in antimicrobial resistance increases demand for older antibiotics.
- Patent expiries and generic manufacturing reduce prices.
- Supply chain disruptions, such as COVID-19, impacted availability and pricing last year.
Future Price Projections (2023-2028)
| Year | API Price (USD/g) | Final Dosage Price (USD/tablet) | Market Drivers |
|---|---|---|---|
| 2023 | 0.40 - 0.65 | 0.15 - 0.55 | Continued generics competition, increased antimicrobial resistance demand |
| 2024 | 0.35 - 0.60 | 0.12 - 0.50 | Cost efficiencies, regulatory tightening reduces new entrants |
| 2025 | 0.35 - 0.55 | 0.10 - 0.45 | Sustained demand in low-income areas, resistance-driven need |
| 2026 | 0.30 - 0.50 | 0.10 - 0.40 | Further market consolidation, API price stabilization |
| 2027 | 0.30 - 0.45 | 0.09 - 0.38 | Global antimicrobial stewardship efforts may limit volume growth |
What Are the Competitive and Strategic Implications?
Market Players
- Multiple generic API producers dominate, especially in India and China.
- Brand-name versions are largely phased out or highly restricted.
- International organizations promote quality standards to avoid substandard products.
Entry Barriers
- Regulatory approval for new formulations is complex.
- Limited innovation interest due to resistance and shifting treatment paradigms.
- Price pressures from commoditized API manufacturing.
Opportunities
- Development of combination drugs or formulations for resistant strains.
- Focus on geographic markets with high unmet needs.
- Investment in manufacturing efficiencies to maintain cost competitiveness.
Key Challenges and Risks
- Growing antimicrobial stewardship policies could restrict usage.
- Resistance diminishes clinical utility, reducing demand.
- Regulatory restrictions may prohibit new marketing authorizations.
- Potential supply disruptions from geopolitical or manufacturing issues.
Key Takeaways
- Sulfadiazine's market size remains modest and regionally variable, heavily reliant on low-cost manufacturing.
- Price per gram for API is expected to decline gradually through 2028, driven by generics competition.
- Regulatory restrictions and antimicrobial resistance will influence future demand.
- The primary growth opportunity exists in underserved regions with high infectious disease prevalence.
- Companies focusing on cost efficiencies and quality standards will retain competitiveness.
FAQs
1. Is sulfadiazine still an approved medication in major markets?
Yes, but its use is limited. In the US and Europe, it is not approved for new indications but remains available for specific cases or compounded formulations.
2. What are the main indications driving demand?
Treatment of toxoplasmosis, chlamydia, and skin bacterial infections remain primary. Use in ophthalmic preparations also sustains some demand.
3. How do regulatory policies affect sulfadiazine pricing?
Tighter regulations and antimicrobial stewardship reduce new market entries and restrict usage, leading to price stabilization or reductions in API costs.
4. Which regions are expected to sustain the highest demand?
South Asia and Africa exhibit stable or growing demand due to infectious disease prevalence and limited access to newer antibiotics.
5. What are the main competitive advantages for producers?
Low-cost sourcing, compliance with quality standards, and ability to meet regional demand are critical.
References
[1] MarketWatch. (2022). Global Antibiotics Market Analysis.
[2] World Health Organization. (2021). Antimicrobial Resistance: Global Report.
[3] IMS Health. (2022). Pharmaceutical Market Trends.
[4] European Medicines Agency. (2022). Summary of Product Characteristics for Sulfadiazine.
[5] Indian Pharmaceutical Industry Association. (2022). API Manufacturing and Export Data.
More… ↓
